PET-based human dosimetry of18F-Galacto-RGD, a new radiotracer for imaging αvβ3 expression

Journal of Nuclear Medicine

Volumn 47, Issue 5, 2006, Pages 763-769

  Beer, Ambros J ^a,b   Haubner, Roland ^a   Wolf, Ingo ^a   Goebel, Michael ^a   Luderschmidt, Stephan ^a   Niemeyer, Markus ^a   Grosu, Anca Ligia ^a   Martinez, Maria Jose ^a   Wester, Hans Jürgen ^a   Weber, Wolfgang A ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

v 3 expression; 18F Galacto RGD; Dosimetry; PET; Whole body biodistribution

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; FLUORODEOXYGLUCOSE F 18; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; DIAGNOSTIC AGENT; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BLADDER WALL; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEMALE; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MELANOMA; MUSCULOSKELETAL DISEASE; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; URINARY EXCRETION; CHEMISTRY; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; NEOPLASM; RADIOMETRY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 33745548133     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100.
2. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002;2:83-90.
3. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
4. Dredge K, Dalgleish AG, Marriott JB. Recent developments in antiangiogenic therapies. Expert Opin Biol Ther. 2002;2:953-966.
5. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491-497.
6. Aumailley M, Gurrath M, Muller G, et al. Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 1991;291:50-54.
7. Haubner RH, Wester HJ, Weber WA, Schwaiger M. Radiotracer based strategies to image angiogenesis. Q J Nucl Med. 2003;47:189-199.
8. Haubner R, Wester HJ. Radiolabeled tracer for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10:1439-1455.
9. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071.
10. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
11. 18F]Galacto-RGD: synthesis, radio-labelling, metabolic stability and radiation dose estimates. Bioconjugate Chem. 2004;15:61-69.
12. 11C]raclopride in healthy volunteers. Eur J Nucl Med Mol Imaging. 2005;32:952-958.
13. 18F-fluoro-A85380 in healthy volunteers. J Nucl Med. 2003;44:596-601.
14. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
15. 18FFluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482-1488.
16. 18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med. 2001;42:1225-1234.
17. 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 2005;32:764-770.
18. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
19. Kuemmerle JF. Occupation of alpha-v-beta-3 integrin by endogenous ligands modulates IGF-I receptor activation and proliferation of human intestinal smooth muscle. Am J Physiol Gastrointest Liver Physiol. September 29, 2005 [Epub ahead of print].
20. Deloar HM, Fujiwara T, Shidahara M, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole body emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565-574.
21. 18F-FDG and comparison with dose estimates from whole body PET. Phys Med Biol. 1999;44:595-606.
22. ICRP Publication 62: Radiological Protection in Biomedical Research. Oxford, U.K.: Pergamon Press; 1991:12.
23. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated review. Curr Mol Med. 2003;3:659-671.
24. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003;20:203-213.
25. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
26. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
27. Gasparini G, Brooks PC, Biganzoli E, et al. Vascular integrin αvβ3: a new prognostic indicator in breast cancer. Clin Cancer Res. 1998;4:2625-2634.
28. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder P, Imhof BA. Integrin αvβ3-expression in colon carcinoma correlates with survival. Mod Pathol. 2001;14:1126-1132.
29. 18F-galacto-RGD. J Nucl Med. 2005;46:184-189.